Get started
Ultragenyx Pharmaceutical, Inc.Ultragenyx Pharmaceutical, Inc.Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsETFs

Live chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.05 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.5 USD
Net income (FY)
‪−569.18 M‬ USD
Revenue (FY)
‪560.23 M‬ USD
Shares float
‪89.64 M‬
Beta (1Y)
0.99

Employees


Employees (FY)
‪1.29 K‬
Change (1Y)
+18 +1.41%
Revenue / Employee (1Y)
‪432.94 K‬ USD
Net income / Employee (1Y)
‪−439.86 K‬ USD

About Ultragenyx Pharmaceutical Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emil D. Kakkis
Website
ultragenyx.com
Headquarters
Novato
Founded
2010
ISIN
US90400D1081
FIGI
BBG00JVXHH87
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Check out other big names from the same industry as 0LIF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


XBI
SPDR S&P BIOTECH ETF
Weight
1.09%
Market value
‪73.64 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.04%
Market value
‪65.28 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
0.09%
Market value
‪36.42 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.04%
Market value
‪30.96 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
0.10%
Market value
‪20.36 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.28%
Market value
‪18.27 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.08%
Market value
‪15.57 M‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
0.01%
Market value
‪11.67 M‬
USD
IWR
iShares Russell Midcap ETF
Weight
0.02%
Market value
‪10.67 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.04%
Market value
‪7.60 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
1.03%
Market value
‪4.47 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 0LIF is 34.2 USD — it has increased by 1.78% in the past 24 hours. Watch Ultragenyx Pharmaceutical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Ultragenyx Pharmaceutical, Inc. stocks are traded under the ticker 0LIF.
0LIF stock has risen by 7.98% compared to the previous week, the month change is a 5.59% rise, over the last year Ultragenyx Pharmaceutical, Inc. has showed a −39.75% decrease.
We've gathered analysts' opinions on Ultragenyx Pharmaceutical, Inc. future price: according to them, 0LIF price has a max estimate of 128.00 USD and a min estimate of 35.00 USD. Watch 0LIF chart and read a more detailed Ultragenyx Pharmaceutical, Inc. stock forecast: see what analysts think of Ultragenyx Pharmaceutical, Inc. and suggest that you do with its stocks.
0LIF reached its all-time high on Feb 9, 2021 with the price of 169.2 USD, and its all-time low was 25.9 USD and was reached on Jul 21, 2025. View more price dynamics on 0LIF chart.
See other stocks reaching their highest and lowest prices.
0LIF stock is 5.31% volatile and has beta coefficient of 0.99. Track Ultragenyx Pharmaceutical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ultragenyx Pharmaceutical, Inc. there?
Today Ultragenyx Pharmaceutical, Inc. has the market capitalization of ‪3.22 B‬, it has increased by 0.37% over the last week.
Yes, you can track Ultragenyx Pharmaceutical, Inc. financials in yearly and quarterly reports right on TradingView.
Ultragenyx Pharmaceutical, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
0LIF earnings for the last quarter are −1.17 USD per share, whereas the estimation was −1.30 USD resulting in a 9.81% surprise. The estimated earnings for the next quarter are −1.23 USD per share. See more details about Ultragenyx Pharmaceutical, Inc. earnings.
Ultragenyx Pharmaceutical, Inc. revenue for the last quarter amounts to ‪166.50 M‬ USD, despite the estimated figure of ‪162.01 M‬ USD. In the next quarter, revenue is expected to reach ‪166.83 M‬ USD.
0LIF net income for the last quarter is ‪−114.95 M‬ USD, while the quarter before that showed ‪−151.08 M‬ USD of net income which accounts for 23.91% change. Track more Ultragenyx Pharmaceutical, Inc. financial stats to get the full picture.
No, 0LIF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 16, 2025, the company has ‪1.29 K‬ employees. See our rating of the largest employees — is Ultragenyx Pharmaceutical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ultragenyx Pharmaceutical, Inc. EBITDA is ‪−469.65 M‬ USD, and current EBITDA margin is −89.33%. See more stats in Ultragenyx Pharmaceutical, Inc. financial statements.
Like other stocks, 0LIF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ultragenyx Pharmaceutical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ultragenyx Pharmaceutical, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ultragenyx Pharmaceutical, Inc. stock shows the sell signal. See more of Ultragenyx Pharmaceutical, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.